EMA Authorised: Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz;emtricitabine;tenofovir disoproxil maleate) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA has authorised the fixed-dose combination therapy Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan for the treatment of HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz; emtricitabine; tenofovir disoproxil)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Mylan Pharmaceuticals Limited. Decision date: 18/11/2025